Media is the core raw material for the production of biological products and plays a very important role
in the biomedical industry.
In recent years, supported by a series of favorable policies, the domestic biological drug market has developed rapidly, and statistics show that a total of 27 domestic monoclonal antibody drugs have been approved in China from 2019 to 2021, far exceeding the number approved
during 2013-2018.
The overall biopharmaceutical market is also expanding, and according to Sullivan Consulting, the biopharmaceutical market is expected to reach 811.
6 billion yuan in 2025
.
In this context, the upstream media industry is also expected to share dividends and usher in rapid growth
.
According to the data, the global cell culture media market is expected to have a CAGR of 10.
76% from 2021 to 2026, and this market is expected to reach $3.
5 billion by 2026.
In 2021, the upstream media market size of the global biopharmaceutical market was about $2.
1 billion, and it is expected that the global media market will maintain growth at a compound annual growth rate of 10.
76% in the next five years, reaching $3.
5 billion
by 2026.
In China, although the biopharmaceutical industry started late, it has developed rapidly, which has also driven the rapid growth of
the culture media market.
Data show that in 2021, the size of China's cell culture media market is 2.
63 billion yuan, and the CAGR of China's cell culture media market is expected to be 22.
0% from 2021 to 2026, and by 2026, the domestic cell culture media market will exceed the 7 billion yuan mark, reaching 7.
1 billion yuan
.
From the perspective of market structure, at present, domestic cell culture media are mainly imported, and even monopolized by imported brands, while domestic production accounts for a relatively small
proportion.
In recent years, with the rapid development of the biopharmaceutical industry and the continuous improvement of the technology of domestic enterprises, domestic head cell culture medium enterprises represented by Opmei and Auscon have also continued to rise
.
The industry expects that under the general trend of medical insurance control fees, centralized procurement and price reduction, and affected by the supply risk of imported products, the trend of domestic substitution of culture medium is expected to accelerate
.
OPMEC disclosed in an institutional survey activity record on November 11 that the rapid development of the culture media industry in recent years is due to the driving effect of the industry, and factors such as supply chain security have accelerated the development of
the industry.
At present, the distribution of pipelines using the company's culture medium at various stages is funnel-shaped, mainly in preclinical and clinical phases I and II, and the number of clinical phase III and commercialization has not changed
compared with the number at the end of last year.
In terms of R&D investment, the company is mainly iterating in two aspects, on the one hand, updating the existing culture medium to improve the universality of the company's commercial culture medium; On the other hand, the expansion of new media product categories and the continuous enrichment of product categories
.
Some domestic media manufacturers with certain strength are also actively going out
.
According to the proportion target of overseas revenue of culture media disclosed by OPMEC in the institutional survey, the overseas market of culture media is expected to account for more than
20% of the overall culture media business this year.
"We have been tracking the layout of overseas markets for many years and have also set up subsidiaries
in the United States.
In the future, we will also vigorously promote
according to the company's development strategy and the actual market situation.
”
According to the news in October, the HEK293 series chemical composition limited media products independently developed by Shanghai Dongfulong Biological Reagent Co.
, Ltd.
were issued by the US FDA DMF Type II type filing acceptance letter
.
This means that the media can assist customers in the dual filing
of antibody drug or macromolecule drug research projects that are in or are planning to conduct clinical applications or new drug registrations.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
